--- title: "北京瑞迈特医疗科技股份有限公司 (301367.SZ)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/301367.SZ.md" symbol: "301367.SZ" name: "北京瑞迈特医疗科技股份有限公司" industry: "医疗器械" --- # 北京瑞迈特医疗科技股份有限公司 (301367.SZ) | Item | Detail | |------|--------| | Industry | 医疗器械 | | Location | 沪深市场 | | Website | [www.bmc-medical.com](https://www.bmc-medical.com) | ## Company Profile 公司于 2001 年成立于北京,我们致力于为全球用户提供睡眠呼吸障碍、慢性呼吸系统疾病的整体服务方案。公司是集自主研发、生产、销售及相关服务于一体的国内呼吸健康领域医疗设备与耗材产品制造龙头企业。公司主要产品包括家用无创呼吸机、通气面罩、睡眠监测仪、高流量湿化氧疗仪、制氧机等。 ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-18T04:30:09.000Z **Overall: B (0.31)** **Industry**: Health Care Equipment | Metric | Value | |--------|-------| | Industry Ranking | 17 / 63 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 34.70% | | | Net Profit YoY | 38.35% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 2.32 | | | Dividend Ratio | 0.51% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 6.92B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 1.05B | | **Multi Score**: B #### Profit Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 7.28% | B | | Profit Margin | 20.03% | A | | Gross Margin | 56.30% | B | #### Growth Score: A | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 34.70% | A | | Net Profit YoY | 38.35% | B | | Total Assets YoY | 8.61% | B | | Net Assets YoY | 6.60% | B | #### Cash Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | 499.17% | C | | OCF YoY | 34.70% | A | #### Operating Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.31 | D | #### Debt Score: A | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 15.08% | A | ```chart-data:radar { "title": "Longbridge Financial Score - 北京瑞迈特医疗科技股份有限公司", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "B", "indicators": [ { "name": "ROE", "value": "7.28%", "rating": "B" }, { "name": "Profit Margin", "value": "20.03%", "rating": "A" }, { "name": "Gross Margin", "value": "56.30%", "rating": "B" } ] }, { "name": "Growth", "grade": "A", "indicators": [ { "name": "Revenue YoY", "value": "34.70%", "rating": "A" }, { "name": "Net Profit YoY", "value": "38.35%", "rating": "B" }, { "name": "Total Assets YoY", "value": "8.61%", "rating": "B" }, { "name": "Net Assets YoY", "value": "6.60%", "rating": "B" } ] }, { "name": "Cash", "grade": "B", "indicators": [ { "name": "Cash Flow Margin", "value": "499.17%", "rating": "C" }, { "name": "OCF YoY", "value": "34.70%", "rating": "A" } ] }, { "name": "Operating", "grade": "D", "indicators": [ { "name": "Turnover", "value": "0.31", "rating": "D" } ] }, { "name": "Security", "grade": "A", "indicators": [ { "name": "Gearing Ratio", "value": "15.08%", "rating": "A" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | 联影医疗 (SH.688271) | B | B | C | B | B | B | | 02 | 鱼跃医疗 (SZ.002223) | B | B | C | A | C | B | | 03 | 惠泰医疗 (SH.688617) | A | B | B | A | B | B | | 04 | 奕瑞科技 (SH.688301) | A | B | E | A | B | B | | 05 | 振德医疗 (SH.603301) | C | B | C | B | B | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 32.93 | 10/66 | 42.72 | 39.59 | 36.33 | | PB | 2.32 | 17/66 | 2.74 | 2.56 | 2.38 | | PS (TTM) | 6.60 | 25/66 | 8.27 | 7.75 | 7.14 | | Dividend Yield | 0.51% | 39/66 | 0.92% | 0.48% | 0.44% | ## Institutional View ### Analyst Rating Distribution > As of 2026-01-06T16:00:00.000Z Total Analysts: **2** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 2 | 100% | | Overweight | 0 | 0% | | Hold | 0 | 0% | | Underweight | 0 | 0% | | Sell | 0 | 0% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 77.27 | | Highest Target | 110.00 | | Lowest Target | 93.08 | ## References - [Company Overview](https://longbridge.com/en/quote/301367.SZ/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/301367.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/301367.SZ/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.